KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082981" target="_blank" >RIV/00216224:14110/15:00082981 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1200/JCO.2014.57.4970" target="_blank" >http://dx.doi.org/10.1200/JCO.2014.57.4970</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2014.57.4970" target="_blank" >10.1200/JCO.2014.57.4970</a>

Result language
angličtina
Original language name
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
Original language description
Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. Patients and Methods We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. Results We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those withKIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)